NEW YORK (GenomeWeb News) – Using whole-genome sequencing in a clinical trial of aromatase-inhibitor therapy for estrogen-positive breast cancer patients, researchers from the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and the Genome Institute at Washington University in St. Louis have found genomic signatures that correlate with drug response and resistance.

The study's results were published online Sunday in Nature.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.